Evaluation of ICP-B381 in Patients With Advanced Solid Tumors

November 13, 2026 updated by: Beijing InnoCare Pharma Tech Co., Ltd.

An Open, Multicenter, Phase I/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics Characteristics, and Efficacy of ICP-B381 in Participants With Advanced Solid Tumors

To evaluate the safety, tolerability, efficacy and pharmacokinetic characteristics of ICP-B381 in the trial participants of advanced solid tumors

Study Overview

Status

Recruiting

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

348

Phase

  • Phase 2
  • Phase 1

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

    • Shanghai Municipality
      • Shanghai, Shanghai Municipality, China, 200032
        • Recruiting
        • Fudan University Shanghai Cancer Center
        • Contact:
          • DingWei Ye, M.D.
          • Phone Number: 021-64175590*81807
          • Email: dwyeli@163.com

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  1. Participants must be at least 18 years old.
  2. Participants thoroughly understand study procedures, and voluntarily sign the written ICF
  3. Eastern Cooperative Oncology Group (ECOG) performance status score 0-1.
  4. Expected survival time ≥3 months.
  5. Histopathologically confirmed metastatic castration-resistant prostate cancer (mCRPC) & Other advanced solid tumor
  6. Agree to provide FFPE slides from archived tumor tissues collected within the past 2 years or fresh tumor biopsies (for archived samples, more recently collected specimens are preferred
  7. The organ function level must meet the prescribed standards
  8. All toxicities derived from previous anti-neoplasm treatments must have been resolved to Grade ≤1 (per CTCAE V6.0)
  9. Effective contraceptive measures should be taken from the date of signing the informed consent form until at least 6 months after the use of the last dose of the study drug
  10. Female participant of childbearing potential must have a negative blood pregnancy test at the screening visit
  11. Female participants must not breastfeed or plan pregnancy during the study and for at least 6 months after the last dose.
  12. Participants can communicate well with the Investigator and can complete the study according to the study protocol

Exclusion Criteria:

  1. Other active malignant tumors occurred within 3 years before the first administration of the study drug
  2. Has previously received or is currently receiving the same type of drug or related treatment as stipulated in the protocol
  3. Has a previous medical history and adverse life history as specified in the protocol, or has a disease as specified in the protocol
  4. Has received cytotoxic chemotherapy, radical radiotherapy, molecular targeted therapy, immunotherapy, anti-tumor vaccine therapy, cytokine therapy, or other investigational anti-cancer drugs with an elution time not meeting the protocol requirements
  5. Had active bleeding within 2 months before screening or had clinically significant or significant bleeding tendency, or was experiencing bleeding symptoms due to taking anticoagulant drugs or other medical interventions
  6. Had major surgery within 28 days before the first administration or minor surgery within 2 weeks before the first administration
  7. Has received systemic immunosuppressive drugs as stipulated in the protocol for 14 days before the first administration
  8. Has a history of severe allergic reactions to the active ingredient, non-active ingredients in the drug, or antibody-based drugs
  9. Had the first administration within 2 weeks before or is planned to use drugs or foods with strong inhibitory or inducing effects on cytochrome P450 CYP3A before the study
  10. Has any mental or cognitive disorders that may limit their understanding, execution of the informed consent form, and compliance with the study
  11. Situations that the investigator deems unsuitable for participating in this study

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: N/A
  • Interventional Model: Sequential Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: ICP-B381

ICP-B381 will be administered by intravenous infusion every 3 weeks (Q3W) until disease progression (PD) or the occurrence of unacceptable toxicity or withdrawal from the study for other reasons (whichever occurs first).

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
The type, severity (assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 6.0 [NCI-CTCAE V6.0]), relationship to the investigational product, and incidence rate of adverse event (AE) and serious advers
Time Frame: 2 years
2 years
The type, severity (assessed according to NCI-CTCAE V6.0), and incidence rate of dose limiting toxicity (DLT)
Time Frame: 2 years
2 years
Single-agent Recommended Dose (RD) and/or Maximum Tolerated Dose (MTD)
Time Frame: 2 years
2 years
Participants with prostate cancer: Prostate-specific antigen (PSA50) response rate
Time Frame: 2 years
2 years
Participants with other tumor types: Investigator-assessed Objective response rate (ORR)
Time Frame: 2 years
2 years
The optimal dosing regimen for the subsequent study of ICP-B381
Time Frame: 2 years
2 years

Secondary Outcome Measures

Outcome Measure
Time Frame
Overall Survival (OS)
Time Frame: 2 years
2 years
Duration of Response (DOR)
Time Frame: 2 years
2 years
Objective response rate (ORR)
Time Frame: 2 years
2 years
Maximum Concentration (Cmax)
Time Frame: 2 years
2 years
Disease Control Rate (DCR)
Time Frame: 2 years
2 years
Time to Maximum Plasma Concentration (Tmax)
Time Frame: 2 years
2 years
Half-life (T1/2)
Time Frame: 2 years
2 years
Area Under the Serum or Plasma Concentration-Time Curve (AUC0-∞ and AUC0-t)
Time Frame: 2 years
2 years
Apparent Clearance Rate (CL/F)
Time Frame: 2 years
2 years
Terminal Apparent Volume of Distribution (Vz/F)
Time Frame: 2 years
2 years
Steady-state Pharmacokinetic Parameters
Time Frame: 2 years
2 years
Participants with prostate cancer: radiographic progression-free survival (rPFS) evaluated by the Investigator according to RECIST V1.1 criteria (for soft tissue lesions) and PCWG3 criteria (for bone lesions)
Time Frame: 2 years
2 years
Participants with prostate cancer: changes in serum PSA levels compared to baseline during the study: PSA50 response rate
Time Frame: 2 years
2 years
Participants with prostate cancer: PSA90 response rate
Time Frame: 2 years
2 years
Participants with prostate cancer:12-week PSA response rate
Time Frame: 2 years
2 years
Participants with prostate cancer: time to PSA progression (TTPP)
Time Frame: 2 years
2 years
Time to First Subsequent Therapy (TFST)
Time Frame: 2 years
2 years
Participants with prostate cancer: incidence rate of symptomatic skeletal event (SSE)
Time Frame: 2 years
2 years
Participants with prostate cancer: time to first symptomatic skeletal event (TTSSE)
Time Frame: 2 years
2 years
Incidence rate of anti-drug antibody (ADA) against ICP-B381
Time Frame: 2 years
2 years
Types, severity (assessed according to NCI-CTCAE V6.0), relationship with the investigational product, and incidence rate of AE and SAE
Time Frame: 2 years
2 years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

October 30, 2026

Primary Completion (Estimated)

September 1, 2027

Study Completion (Estimated)

July 1, 2028

Study Registration Dates

First Submitted

October 22, 2026

First Submitted That Met QC Criteria

October 22, 2026

First Posted (Actual)

October 28, 2026

Study Record Updates

Last Update Posted (Actual)

November 18, 2026

Last Update Submitted That Met QC Criteria

November 13, 2026

Last Verified

November 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • ICP-CL-01901

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe